Bjørn H Ebdrup
Biographic Data
| ID | 5462409 |
|---|---|
| NAME | Bjørn H Ebdrup |
| GIVEN NAMES | Bjørn H |
| FAMILY NAME | Ebdrup |
| SIGNATURE | EBDRUP B H |
| AFFILIATIONS | University of Copenhagen |
| ORCID | 0000-0002-2590-5055 |
| VERIFIED | Yes |
| TOTAL WORKS | 7 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 7 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2019 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Subtle impairments of facial emotion expressions in individuals at ultra-high risk for psychosis
Emotional processing deficits are increasingly recognized as a salient feature of psychotic disorders, and emerging evidence suggests that impairments in facial emotion processing may serve as additive predictive markers for individuals at ultra-high risk (UHR) for psychosis, highlighting the importance of such deficits for early identification and intervention strategies. In this study we examined whether automated coding of facial features from…
Tapered discontinuation vs. maintenance therapy of antipsychotic medication in patients with first-episode schizophrenia
https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000565-23/DK, EU Clinical Trials Register-EudraCT no. 2016-000565-23
Add-On MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis- the Amend Trial Protocol
[ClinicalTrials.gov], identifier [NCT04789915]
Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses
Patients treated with aripiprazole improved on negative symptoms, which was not the case for patients treated with amisulpride. This may point to a general effect of a partial D2 receptor agonist on negative symptoms in patients with first-episode psychoses. There was, however, no improvement in cognitive functions
Fish Oil Supplementation in Pregnancy and Neurodevelopment in Childhood—A Randomized Clinical Trial
A double-blind randomized controlled trial of n-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation or matching placebo during third trimester of pregnancy was conducted within the COPSAC2010 mother-child cohort consisting of 736 women and their children. The objective was to determine if maternal n-3 LCPUFA pregnancy supplementation affects offspring neurodevelopment until 6 years. Neurodevelopment was evaluated in 654 children …
No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosis—A Randomized Clinical Trial
ClinicalTrials.gov, identifier NCT02098408
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
Background: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover. Methods: In planned secondary analyses of a 3 months, double-blind, randomized, placebo-controlled trial ( n = 45), we explored effects of the GLP-1 receptor agonist exenatide 2 m…
No prominent works on this page.
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
Background: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover. Methods: In planned secondary analyses of a 3 months, double-blind, randomized, placebo-controlled trial ( n = 45), we explored effects of the GLP-1 receptor agonist exenatide 2 m…
No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosis—A Randomized Clinical Trial
ClinicalTrials.gov, identifier NCT02098408
Fish Oil Supplementation in Pregnancy and Neurodevelopment in Childhood—A Randomized Clinical Trial
A double-blind randomized controlled trial of n-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation or matching placebo during third trimester of pregnancy was conducted within the COPSAC2010 mother-child cohort consisting of 736 women and their children. The objective was to determine if maternal n-3 LCPUFA pregnancy supplementation affects offspring neurodevelopment until 6 years. Neurodevelopment was evaluated in 654 children …
Tapered discontinuation vs. maintenance therapy of antipsychotic medication in patients with first-episode schizophrenia
https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000565-23/DK, EU Clinical Trials Register-EudraCT no. 2016-000565-23
Add-On MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis- the Amend Trial Protocol
[ClinicalTrials.gov], identifier [NCT04789915]
Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses
Patients treated with aripiprazole improved on negative symptoms, which was not the case for patients treated with amisulpride. This may point to a general effect of a partial D2 receptor agonist on negative symptoms in patients with first-episode psychoses. There was, however, no improvement in cognitive functions
Subtle impairments of facial emotion expressions in individuals at ultra-high risk for psychosis
Emotional processing deficits are increasingly recognized as a salient feature of psychotic disorders, and emerging evidence suggests that impairments in facial emotion processing may serve as additive predictive markers for individuals at ultra-high risk (UHR) for psychosis, highlighting the importance of such deficits for early identification and intervention strategies. In this study we examined whether automated coding of facial features from…
Medicine (6 works) · Psychiatry (6 works) · Internal Medicine (5 works) · Psychology (5 works) · Schizophrenia research and treatment (4 works) · Antipsychotic (3 works) · Cognition (3 works) · Psychosis (3 works) · Randomized controlled trial (3 works) · Schizophrenia (object-oriented programming (3 works)